autophagy disruption

Subsets Mean Success Until now, the heterogeneity of the patient population and the lack of a reliable biomarker to diagnose and prognose ME/CFS has thwarted clinical trials for both non-approved FDA drugs as well as repurposed agents. We have recently identified elevated levels of inactive...